TheraNews Logo

Bright Minds Biosciences Announces Positive Topline Results From Phase 2 Clinical Trial Of BMB-101 In Patients With Absence Seizures And Developmental And Encephalopathic Epilepsies (DEE)

menafn|1/6/2026|depression
Share this article:
Email

Bright Minds Biosciences Announces Positive Topline Results From Phase 2 Clinical Trial Of BMB-101 In Patients With Absence Seizures And Developmental And Encephalopathic Epilepsies (DEE)

ONLY AVAILABLE IN PAID PLANS.


Originally reported by menafn. Read more

Share this article:
Email

Related Articles

More stories about depression